Quality Chemical Industries Limited
| Formerly | Cipla Quality Chemical Industries Limited - CiplaQCIL |
|---|---|
| Company type | Public USE: Qcil |
| Industry | Pharmaceutical Industry |
| Founded | July 10, 2005 |
| Headquarters | Luzira, Kampala, Uganda |
Area served | Africa |
Key people | Emmanuel Katongole Executive Chairman Ajay Kumar Pal Chief Executive Officer |
| Products | Pharmaceuticals |
| Revenue | :USh265.3 billion (US$70.9 million) (March 2024) |
| Total assets | USh232.0 billion (US$60.1 million) (March 2024) |
Number of employees | 360 (2024) |
| Website | www |
Quality Chemical Industries Limited (Qcil), formerly Cipla Quality Chemical Industries Limited (CiplaQCIL) is a pharmaceutical manufacturing company, established in Uganda by Ugandans in 2005. The company is committed to advancing wellness and is the largest producer of World Health Organization (WHO) pre-qualified HIV/AIDS and Malaria treatments in the region. According to a 2007 published report, Qcil was the only company in Africa to manufacture triple-combination antiretroviral (ARV) drugs. Qcil currently produces TLD (a combination of tenofovir, lamivudine and dolutegravir), the latest first-line treatment used to treat and prevent HIV/AIDS. Qcil also manufactures antimalarials (ACTs), including Lumartem, containing artemisinin and lumefantrine, and the Hepatitis B generic medicines Texavir and Zentair.
The company also manufactures antibacterials, anti-hypertensives, vasodilators, anti-emetics, antibiotics and antidiabetics.
Qcil’s state-of-the-art manufacturing facilities are GLP and cGMP-compliant, adhering to both national and international standards. The company has the following ISO certifications: 9001:2015, 14001:2015, and 45001:2018.